公开(公告)号：US20190336684A1

公开(公告)日：2019-11-07

申请号：US16404456

申请日：2019-05-06

Applicant: Insulet Corporation

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61M5/142 ,  A61M5/145 ,  A61B5/145

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US20240424212A1

公开(公告)日：2024-12-26

申请号：US18824363

申请日：2024-09-04

Applicant: INSULET CORPORATION

Inventor： Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Mert SEVIL ,  William WHITELEY ,  Saeed SALAVATI ,  Sam CARL

IPC: A61M5/172

Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.

公开(公告)号：US20240293617A1

公开(公告)日：2024-09-05

申请号：US18436410

申请日：2024-02-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Mengdi LI ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  H04L67/141

CPC classification number: A61M5/1723 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61M2202/07 ,  A61M2205/3584 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2230/20 ,  A61M2230/201 ,  H04L67/141

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US20240226433A1

公开(公告)日：2024-07-11

申请号：US18390338

申请日：2023-12-20

Applicant: INSULET CORPORATION

Inventor： Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Mert SEVIL ,  William WHITELEY ,  Saeed SALAVATI ,  Sam CARL

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2230/201

Abstract: The exemplary embodiments may provide a drug delivery device that receives glucose level values for a user (e.g., a diabetic patient) and based on the glucose level values, determines when the user has consumed a meal. In some embodiments, the drug delivery device may calculate an appropriate bolus dose and automatically deliver the drug bolus to the user. In some embodiments, instead of detecting the meal, the user may announce the meal, such as by activating an element on the drug delivery device or on a management device for the drug delivery device. Responsive to the meal announcement, the drug delivery device may calculate the drug bolus dose and deliver the drug bolus. In conjunction with the delivery of the drug bolus, the drug delivery device may relax one or more safety constraints for a relaxation period following the drug bolus delivery so that additional basal drug may be delivered, if needed, under relaxed constraints.

公开(公告)号：US20240148971A1

公开(公告)日：2024-05-09

申请号：US18386647

申请日：2023-11-03

Applicant: INSULET CORPORATION

Inventor： Matthew ALLES ,  Yibin ZHENG ,  Joon Bok LEE ,  James CAUSEY ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  A61M2202/0486

Abstract: Exemplary embodiments may provide an on-body medicament delivery system that provides basal delivery of a medicament to a type 2 diabetes patient and that automatically performs medicament titration for the patient. The medicament delivery system performs medicament titration based on glucose level readings for the patient. These glucose levels may be provided wirelessly from a glucose sensor, such as a continuous glucose monitor, or may be entered manually by the patient into a management device, such as a smartphone running an application that provides a user interface for the patient to enter the glucose level readings. The medicament delivery system adjusts the basal medicament delivery rate/dose based on the glucose level readings for the patient. The adjustments may be performed by a programmatic mechanism, such as by computer programming instructions executing on a processor.

公开(公告)号：US20240066213A1

公开(公告)日：2024-02-29

申请号：US18453765

申请日：2023-08-22

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O’CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/142 ,  A61M5/172

CPC classification number: A61M5/14248 ,  A61M5/1723 ,  A61M2202/0486

Abstract: Disclosed are techniques, devices and systems that modify an insulin delivery schedule based on how sensitive a diabetic user may to fluctuations in their total daily insulin or fluctuations in their blood glucose measurement values. As a control algorithm calculates how to adapt the calculation of the user's total daily insulin, a rate of adaptivity function may be used in the calculation. The rate of adaptivity may depend on a number of factors and the disclosed techniques, devices and systems enable calculation of the rate of adaptivity to provide effective implementation or modification of a diabetic treatment plan.

公开(公告)号：US20230355874A1

公开(公告)日：2023-11-09

申请号：US18353523

申请日：2023-07-17

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Bonnie DUMAIS ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2230/201

Abstract: Disclosed are techniques and devices that are operable to receive one or a number of generalized parameters of an automated insulin delivery algorithm. An input of at least one generalized parameter corresponding to a user may be used to set one or more of the number of specific parameters of the automated insulin delivery algorithm based on the inputted at least one generalized parameter. Physiological condition data related to the user may be collected. The automated insulin delivery algorithm may determine a dosage of insulin to be delivered based on the collected physiological condition. Signals may be output to cause a liquid drug to be delivered to the user based on an output of the automated insulin delivery algorithm related to the determined dosage of insulin.

公开(公告)号：US20230310741A1

公开(公告)日：2023-10-05

申请号：US18192380

申请日：2023-03-29

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE ,  James CAUSEY

IPC: A61M5/172

CPC classification number: A61M5/172 ,  A61M2205/50

Abstract: Disclosed herein is a drug delivery system wherein wearable components of the system are provided with Wi-Fi and/or cellular capabilities such as to allow different modalities for inter-component communications and, further, to allow access to a plethora of cloud-based services to enhance the functionality of the system.

公开(公告)号：US20230248909A1

公开(公告)日：2023-08-10

申请号：US18164669

申请日：2023-02-06

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  James GRAHAM ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/0486 ,  A61M2205/52

Abstract: Disclosed are processes and techniques for a correction factor determination process for determining a correction factor for delivering a drug to a patient via a drug delivery device. For example, for an insulin delivery device, the disclosed techniques enable adjustment of the patient’s correction factor in real time based on the deviation of the patient’s glucose concentrations against clinically recommended targets. For example, a method for determining a correction factor may include determining an insulin action (Iaction) for a patient over a duration, the insulin action representing a total insulin metabolized, determining glucose information for the patient over the duration, the glucose information representing glucose activity, and determining an estimated correction factor (CFest) based on (glucose information) / (insulin action) for the duration. Other embodiments are described.

公开(公告)号：US20230233762A1

公开(公告)日：2023-07-27

申请号：US18156497

申请日：2023-01-19

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Kerrie GALLAGHER ,  Lindsay PHILBRICK ,  Alex NGUYEN ,  Joshua WILLIAMS

IPC: A61M5/172 ,  A61B5/145

CPC classification number: A61M5/172 ,  A61B5/14532 ,  A61M2230/201

Abstract: Exemplary embodiments may provide a user interface and logic for assisting a user in calculating a proper medicament bolus dosage. The user interface may be simple and easy to understand. The user interface may clearly specify needed inputs, such as a carbohydrates amount for a meal that is about to be ingested and the current glucose level reading for the user. Entered inputs may be displayed on the user interface. The user interface may depict key calculated values resulting from calculations that involve the inputs, including the total bolus dosage calculation. The user interface also may depict the values that contribute to the total bolus dosage calculation. Some of the input values, such as carbohydrates amount, may be prepopulated by the management device or medicament delivery device. The user interface may permit overriding of prepopulated input values.